Tessa Therapeutics Appoints Mr. Desmond Lim as Chief Financial Officer

SINGAPORE, Dec. 12, 2017 /PRNewswire/ -- Tessa Therapeutics, a clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for solid tumors, today announces the appointment of Mr. Desmond Lim as Chief Financial Officer.

Mr. Lim has over 25 years of finance experience and has held multiple senior executive roles in the recent decade. He started his career in auditing with Arthur Andersen & Co in Australia, followed by treasury and capital markets roles at Deutsche Bank and at GE Capital. Desmond worked as Vice President and Asia Pacific Chief Financial Officer at Honeywell International and as Global Treasurer at Avago Technologies (now Broadcom), which was listed on NASDAQ in August 2009. Desmond is joining Tessa from Heptagon, a developer and manufacturer of advanced micro-optics based solutions and systems in the semiconductor segment, where he was the Chief Financial Officer and successfully took the company through a strategic acquisition process by a European listed conglomerate.

Commenting on his new role, Mr. Lim said, "I am very happy to be a part of the Tessa family and excited by the future growth plans that the company has in store. Tessa has achieved amazing progress in a very short period of time. This is a testament to the impressive team the company has assembled. I am looking forward to being part of this team and together taking Tessa to its next stage of growth. Immunotherapy is fast becoming a key component of cancer treatment and the work at Tessa is at the frontier of this field."

Tessa Therapeutics co-founder and CEO, Mr. Andrew Khoo said, "I am delighted to welcome Desmond to Tessa. The deep experience he brings to our senior management team will no doubt be valuable on our growth trajectory as a global biotechnology company with a growing platform of clinical trials at various stages from Phase I to Phase III. Desmond's finance and capital markets skills will complement our strong scientific platform, clinical trial program, and international production and logistics network. We are excited and ready for the future."

***

About Tessa Therapeutics

Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body's potent anti-viral immune response to recognize and kill cancer cells. Tessa's core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies. Tessa's lead Phase III trial for nasopharyngeal carcinoma (NPC) is the world's largest Phase III T cell immunotherapy trial for any cancer indication. The company has built up robust operational and supply chain capabilities to successfully deliver autologous T cell therapy treatments to a large patient pool across five countries. The combination of technologies from its academic, clinical, and commercial research partners have enabled the company to create a fully-integrated approach to the treatment of cancer with immunotherapy.

For more information on Tessa, please visit www.tessatherapeutics.com.

Media Contact:
Brunswick Group
Will Carnwath, Ben Fry
[email protected]
+65 6426 8188

Investor Contact:
Trout Group
Pete Rahmer
[email protected]
+1 646-378-2973

SOURCE Tessa Therapeutics